We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
As we await news reports from companies reporting Q3 results this morning, we see the October Empire State Index — which had been expected out this morning — was released in error yesterday, with a headline of 4.0. This is better than the 2.0 expected, and between recent highs (+24.3 in August 2018) and lows (-8.6 in June 2019).
Clearly, these results tend toward the more volatile, although interestingly, the estimates for this New York state production survey are almost always higher than the actual — though not for this month. This index looks to be bouncing off those recent lows; the end of the year will be key for this metric.
JPMorgan Chase (JPM - Free Report) , a Zacks Rank #3 (Hold) company, outperformed expectations on both top and bottom lines: $2.68 per share versus $2.44 expected. Revenues came in at $29.3 billion, above the $28.4 billion analysts were looking for. Fixed Income, working off a relatively weak year-over-year comp, was up 25% in Q3 2019, while Credit Loss Provisions rose 60% from the year-ago quarter.
Shares at this hour in the pre-market are up 1.9% on the news, and +7% year to date. JPMorgan has only come up short of earnings estimates once since Q1 2016. For more on JPM’s earnings, click here.
Johnson & Johnson (JNJ - Free Report) , a Zacks Rank #4 (Sell)-rated stock ahead of its earnings report, beat estimates on both top and bottom lines this morning: $2.12 per share amounted to a 12-cent positive surprise, on sales of $20.73 billion which surpassed the $20.08 billion expected. Sales in its important Pharma space rose 5.1%.
J&J raised earnings guidance for full-year 2019 — up 9 cents on the bottom end of the range and +4 cents on the top, to $8.67 per share. Shares are up 1.66% at this moment of pre-market trading, coming up from its near-lows year to date. For more on JNJ’s earnings, click here.
These amount to just a sample of what we are about to see in the days and weeks ahead. Will Q3 bear out better than expected, or are we destined for an earnings recession? For a comprehensive view on the subject, check out this interview with Zacks Director of Research Sheraz Mian: Are We In an Earnings Recession?
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Initial Q3 Results Are Better-Than-Expected
As we await news reports from companies reporting Q3 results this morning, we see the October Empire State Index — which had been expected out this morning — was released in error yesterday, with a headline of 4.0. This is better than the 2.0 expected, and between recent highs (+24.3 in August 2018) and lows (-8.6 in June 2019).
Clearly, these results tend toward the more volatile, although interestingly, the estimates for this New York state production survey are almost always higher than the actual — though not for this month. This index looks to be bouncing off those recent lows; the end of the year will be key for this metric.
JPMorgan Chase (JPM - Free Report) , a Zacks Rank #3 (Hold) company, outperformed expectations on both top and bottom lines: $2.68 per share versus $2.44 expected. Revenues came in at $29.3 billion, above the $28.4 billion analysts were looking for. Fixed Income, working off a relatively weak year-over-year comp, was up 25% in Q3 2019, while Credit Loss Provisions rose 60% from the year-ago quarter.
Shares at this hour in the pre-market are up 1.9% on the news, and +7% year to date. JPMorgan has only come up short of earnings estimates once since Q1 2016. For more on JPM’s earnings, click here.
Johnson & Johnson (JNJ - Free Report) , a Zacks Rank #4 (Sell)-rated stock ahead of its earnings report, beat estimates on both top and bottom lines this morning: $2.12 per share amounted to a 12-cent positive surprise, on sales of $20.73 billion which surpassed the $20.08 billion expected. Sales in its important Pharma space rose 5.1%.
J&J raised earnings guidance for full-year 2019 — up 9 cents on the bottom end of the range and +4 cents on the top, to $8.67 per share. Shares are up 1.66% at this moment of pre-market trading, coming up from its near-lows year to date. For more on JNJ’s earnings, click here.
These amount to just a sample of what we are about to see in the days and weeks ahead. Will Q3 bear out better than expected, or are we destined for an earnings recession? For a comprehensive view on the subject, check out this interview with Zacks Director of Research Sheraz Mian: Are We In an Earnings Recession?